Collaborations

PharmaEngine works with a quality set of partners and collaborators to ensure the best expertise and technologies are applied to our development efforts.

Merrimack Pharmaceuticals, Inc.(Cambridge, MA, USA)

Merrimack is a biopharmaceutical company dedicated to the discovery and development of novel medicines for the treatment of cancer. PharmaEngine licensed in the exclusive rights to develop and commercialize PEP02 in Asia from Hermes BioSciences, Inc in 2003, and subsequently expanded the territory to Europe in 2005. Hermes retained the rights in North America and all other territories. Hermes was acquired by Merrimack Pharmaceuticals, Inc. in 2009.

In May 2011, PharmaEngine and Merrimack executed a License and Colaboration Agreement under which PharmaEngine granted back to Merrimack the rights to develop, manufacture, and commercialize PEP02 (known under the designation of MM-398 by Merrimack) in Asia and Europe, with the exception of Taiwan.